High <scp>CD34</scp>‐positive cell dose in matched unrelated donor allogeneic hematopoietic stem cell transplant is not associated with graft‐versus‐host disease or mortality
Zachary M. Avigan(Tisch Hospital), Richard L. Haspel(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Ajoy Dias(The University of Kansas Cancer Center), David Avigan(Beth Israel Deaconess Medical Center), Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), Laura E. Dodge(Beth Israel Deaconess Medical Center), Matthew Weinstock(Beth Israel Deaconess Medical Center), Jessica Liegel(Beth Israel Deaconess Medical Center), Jon Arnason(Beth Israel Deaconess Medical Center)
Cited by 2
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k